Effects of repeated doses of intravenous immunoglobulin in XXXX .

@entity1 @entity228 @entity1737 @entity934
The authors administered repeated courses of intravenous immunoglobulin (IVIg) to nine @entity1 at the onset of an exacerbation of generalized @entity1737 ( @entity1737 ). Anticholinesterase medication (nine @entity1 ) and @entity228 dosage (six @entity1 ) had been kept constant for a 2-month period. Six @entity1 received two courses, two @entity1 received three courses, and one @entity1 received five courses. Twenty of 23 courses resulted in satisfactory improvement beginning 4.3 +/- 1.2 days after start of IVIg and becoming maximal 8.2 +/- 2.0 days, with sustained improvement lasting 106.6 +/- 49.1 days. Vital capacity increased from an average of 1845.1 +/- 489 cc to 2894 +/- 762 cc (p less than 0.01) at peak effect. Four of nine @entity1 had a decrease in strength before improvement. There was no significant change in @entity934 receptor antibody titers before or after therapy. Side effects were minimal. Of the three @entity1 who had nonsatisfactory course, two responded well to additional IVIg. IVIg can produce repeated beneficial effects in @entity1 with @entity1737 and may be useful as an adjunct in the management of @entity1737 .
